Liver health may change how a promising cancer drug works in the body

NCT ID NCT07677358

Not yet recruiting Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study investigates how the experimental cancer drug atirmociclib is processed by the body in people with mild, moderate, or severe liver disease compared to those with healthy livers. Participants receive a single oral dose of the drug, and blood samples are taken over time to measure drug levels. The goal is to see if liver impairment alters how the drug behaves, which could guide safer dosing for patients with liver issues. The study involves about 28 adults and lasts roughly 9 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
atirmociclib
What this could lead to
If successful, this study could help doctors determine the right dose of atirmociclib for patients with liver problems, making the drug safer to use.
What could go wrong
This is an early-phase study with only 28 participants, so results may not apply to everyone. The drug may still cause side effects regardless of liver function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver disorder liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Floridian Clinical Research

    Miami Lakes, Florida, 33016, United States

  • Genesis Clinical Research

    Tampa, Florida, 33603, United States

  • Orlando Clinical Research Center

    Orlando, Florida, 32809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.